Evaluation of a DNA vaccine candidate expressing prM-E-NS1 antigens of dengue virus serotype 1 with or without granulocyte-macrophage colony-stimulating factor (GM-CSF) in immunogenicity and protection

Vaccine

Volumn 29, Issue 4, 2011, Pages 763-771

  Zheng, Qun ^a   Fan, Dongying ^a   Gao, Na ^a   Chen, Hui ^a   Wang, Juan ^a   Ming, Ying ^a   Li, Jieqiong ^a   An, Jing ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Adjuvant; Dengue virus; DNA vaccine; Granulocyte macrophage colony stimulating factor

Indexed keywords

DNA VACCINE; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN G; INTERLEUKIN 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DENGUE VIRUS 1; DRUG MECHANISM; FEMALE; GENE; IMMUNIZATION; IMMUNOGENICITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PRM E NS1 GENE;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, VIRAL; ANTIGENS, VIRAL; DENGUE; DENGUE VIRUS; DISEASE MODELS, ANIMAL; FEMALE; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; IMMUNIZATION; IMMUNOGLOBULIN G; INTERFERON-GAMMA; INTERLEUKIN-2; LEUKOCYTES, MONONUCLEAR; MICE; MICE, INBRED BALB C; PLASMIDS; SPLEEN; T-LYMPHOCYTES, CYTOTOXIC; VACCINES, DNA;

EID: 78650554142     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.11.014     Document Type: Article

References (37)

1. Halstead S.B. Dengue. Lancet 2007, 370(November (9599)):1644-1652.
2. Leyssen P., De Clercq E., Neyts J. Perspectives for the treatment of infections with Flaviviridae. Clin Microbiol Rev 2000, 13(January (1)):67-82. [Table of contents].
3. Whitehorn J., Farrar J. Dengue. Br Med Bull 2010, 95:161-173.
4. Chambers T.J., Tsai T.F., Pervikov Y., Monath T.P. Vaccine development against dengue and Japanese encephalitis: report of a World Health Organization meeting. Vaccine 1997, 15(October (14)):1494-1502.
5. Sabchareon A., Lang J., Chanthavanich P., Yoksan S., Forrat R., Attanath P., et al. Safety and immunogenicity of a three dose regimen of two tetravalent live-attenuated dengue vaccines in five- to twelve-year-old Thai children. Pediatr Infect Dis J 2004, 23(February (2)):99-109.
6. Sabchareon A., Lang J., Chanthavanich P., Yoksan S., Forrat R., Attanath P., et al. Safety and immunogenicity of tetravalent live-attenuated dengue vaccines in Thai adult volunteers: role of serotype concentration, ratio, and multiple doses. Am J Trop Med Hyg 2002, 66(March (3)):264-272.
7. Innis B.L., Eckels K.H. Progress in development of a live-attenuated, tetravalent dengue virus vaccine by the United States Army Medical Research and Materiel Command. Am J Trop Med Hyg 2003, 69(December (6 Suppl.)):1-4.
8. Guirakhoo F., Pugachev K., Zhang Z., Myers G., Levenbook I., Draper K., et al. Safety and efficacy of chimeric yellow fever-dengue virus tetravalent vaccine formulations in nonhuman primates. J Virol 2004, 78(May (9)):4761-4775.
9. Guirakhoo F., Kitchener S., Morrison D., Forrat R., McCarthy K., Nichols R., et al. Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax-DEN2) vaccine: phase I clinical trial for safety and immunogenicity: effect of yellow fever pre-immunity in induction of cross neutralizing antibody responses to all 4 dengue serotypes. Hum Vaccine 2006, 2(March-April (2)):60-67.
10. Guy B., Nougarede N., Begue S., Sanchez V., Souag N., Carre M., et al. Cell-mediated immunity induced by chimeric tetravalent dengue vaccine in naive or flavivirus-primed subjects. Vaccine 2008, 26(October (45)):5712-5721.
11. Guirakhoo F., Pugachev K., Arroyo J., Miller C., Zhang Z.X., Weltzin R., et al. Viremia and immunogenicity in nonhuman primates of a tetravalent yellow fever-dengue chimeric vaccine: genetic reconstructions, dose adjustment, and antibody responses against wild-type dengue virus isolates. Virology 2002, 298(June (1)):146-159.
12. Imoto J., Konishi E. Dengue tetravalent DNA vaccine increases its immunogenicity in mice when mixed with a dengue type 2 subunit vaccine or an inactivated Japanese encephalitis vaccine. Vaccine 2007, 25(January (6)):1076-1084.
13. Gao N., Chen W., Zheng Q., Fan D.Y., Zhang J.L., Chen H., et al. Co-expression of Japanese encephalitis virus prM-E-NS1 antigen with granulocyte-macrophage colony-stimulating factor enhances humoral and anti-virus immunity after DNA vaccination. Immunol Lett 2010, 129(March (1)):23-31.
14. Kochel T., Wu S.J., Raviprakash K., Hobart P., Hoffman S., Porter K., et al. Inoculation of plasmids expressing the dengue-2 envelope gene elicit neutralizing antibodies in mice. Vaccine 1997, 15(April (5)):547-552.
15. Costa S.M., Freire M.S., Alves A.M. DNA vaccine against the non-structural 1 protein (NS1) of dengue 2 virus. Vaccine 2006, 24(May (21)):4562-4564.
16. Fan W.F., Mason P.W. Membrane association and secretion of the Japanese encephalitis virus NS1 protein from cells expressing NS1 cDNA. Virology 1990, 177(August (2)):470-476.
17. Schlesinger J.J., Foltzer M., Chapman S. The Fc portion of antibody to yellow fever virus NS1 is a determinant of protection against YF encephalitis in mice. Virology 1993, 192(January (1)):132-141.
18. Lin Y.L., Chen L.K., Liao C.L., Yeh C.T., Ma S.H., Chen J.L., et al. DNA immunization with Japanese encephalitis virus nonstructural protein NS1 elicits protective immunity in mice. J Virol 1998, 72(January (1)):191-200.
19. Lee S.W., Cho J.H., Sung Y.C. Optimal induction of hepatitis C virus envelope-specific immunity by bicistronic plasmid DNA inoculation with the granulocyte-macrophage colony-stimulating factor gene. J Virol 1998, 72(October (10)):8430-8436.
20. Chang S.Y., Lee K.C., Ko S.Y., Ko H.J., Kang C.Y. Enhanced efficacy of DNA vaccination against Her-2/neu tumor antigen by genetic adjuvants. Int J Cancer 2004, 111(August (1)):86-95.
21. Puri B., Polo S., Hayes C.G., Falgout B. Construction of a full length infectious clone for dengue-1 virus Western Pacific, 74 strain. Virus Genes 2000, 20(1):57-63.
22. Yang B., Lan X., Li X., Yin X., Li B., Han X., et al. A novel bi-functional DNA vaccine expressing VP1 protein and producing antisense RNA targeted to 5'UTR of foot-and-mouth disease virus can induce both rapid inhibitory effect and specific immune response in mice. Vaccine 2008, 26(October (43)):5477-5483.
23. Chen H.W., Pan C.H., Huan H.W., Liau M.Y., Chiang J.R., Tao M.H. Suppression of immune response and protective immunity to a Japanese encephalitis virus DNA vaccine by coadministration of an IL-12-expressing plasmid. J Immunol 2001, 166(June (12)):7419-7426.
24. Clements D.E., Coller B.A., Lieberman M.M., Ogata S., Wang G., Harada K.E., et al. Development of a recombinant tetravalent dengue virus vaccine: immunogenicity and efficacy studies in mice and monkeys. Vaccine 2010, 28(March (15)):2705-2715.
25. Kaufman B.M., Summers P.L., Dubois D.R., Cohen W.H., Gentry M.K., Timchak R.L., et al. Monoclonal antibodies for dengue virus prM glycoprotein protect mice against lethal dengue infection. Am J Trop Med Hyg 1989, 41(5):576-580.
26. Huisman W., Martina B.E., Rimmelzwaan G.F., Gruters R.A., Osterhaus A.D. Vaccine-induced enhancement of viral infections. Vaccine 2009, 27(January (4)):505-512.
27. Krishna V.D., Rangappa M., Satchidanandam V. Virus-specific cytolytic antibodies to nonstructural protein 1 of Japanese encephalitis virus effect reduction of virus output from infected cells. J Virol 2009, 83(May (10)):4766-4777.
28. Costa S.M., Paes M.V., Barreto D.F., Pinhao A.T., Barth O.M., Queiroz J.L., et al. Protection against dengue type 2 virus induced in mice immunized with a DNA plasmid encoding the non-structural 1 (NS1) gene fused to the tissue plasminogen activator signal sequence. Vaccine 2006, 24(January (2)):195-205.
29. De Paula S.O., Lima D.M., de Oliveira Franca R.F., Gomes-Ruiz A.C., da Fonseca B.A. A DNA vaccine candidate expressing dengue-3 virus prM and E proteins elicits neutralizing antibodies and protects mice against lethal challenge. Arch Virol 2008, 153(12):2215-2223.
30. Blair P.J., Kochel T.J., Raviprakash K., Guevara C., Salazar M., Wu S.J., et al. Evaluation of immunity and protective efficacy of a dengue-3 pre-membrane and envelope DNA vaccine in Aotus nancymae monkeys. Vaccine 2006, 24(February (9)):1427-1432.
31. Ocazionez Jimenez R., Lopes da Fonseca B.A. Recombinant plasmid expressing a truncated dengue-2 virus E protein without co-expression of prM protein induces partial protection in mice. Vaccine 2000, 19(November (6)):648-654.
32. Wu S.F., Liao C.L., Lin Y.L., Yeh C.T., Chen L.K., Huang Y.F., et al. Evaluation of protective efficacy and immune mechanisms of using a non-structural protein NS1 in DNA vaccine against dengue 2 virus in mice. Vaccine 2003, 21(September (25-26)):3919-3929.
33. Ross T.M. Dengue virus. Clin Lab Med 2010, 30(March (1)):149-160.
34. Raviprakash K., Ewing D., Simmons M., Porter K.R., Jones T.R., Hayes C.G., et al. Needle-free Biojector injection of a dengue virus type 1 DNA vaccine with human immunostimulatory sequences and the GM-CSF gene increases immunogenicity and protection from virus challenge in Aotus monkeys. Virology 2003, 315(October (2)):345-352.
35. Darrah P.A., Hegde S.T., Patel D.T., Lindsay R.W., Chen L., Roederer M., et al. IL-10 production differentially influences the magnitude, quality, and protective capacity of Th1 responses depending on the vaccine platform. J Exp Med 2010, 207(July (7)):1421-1433.
36. Meriggioli M.N., Sheng J.R., Li L., Prabhakar B.S. Strategies for treating autoimmunity: novel insights from experimental myasthenia gravis. Ann N Y Acad Sci 2008, 1132:276-282.
37. Sheng J.R., Li L.C., Ganesh B.B., Prabhakar B.S., Meriggioli M.N. Regulatory T cells induced by GM-CSF suppress ongoing experimental myasthenia gravis. Clin Immunol 2008, 128(August (2)):172-180.